Medical management of a suspected atrial myxoma in a nonagenarian

Jessica Kawall1, Rajeev Seecheran1, Valmiki Seecheran1, Sangeeta Persad1, Stefan Maharaj2 and Naveen Anand Seecheran3

Abstract
Cardiac myxomas are the most frequently encountered tumors of the heart. However, they are unusual to be newly diagnosed in the geriatric population. Myxomas are among the great mimickers, with a myriad of clinical presentations related to heart failure, embolic events, and constitutional symptoms. We describe a rare case of a giant atrial myxoma in a nonagenarian presenting with heart failure, which was medically managed.

Keywords
Atrial myxoma, nonagenarian, heart failure, polypharmacy

Case Report
A 94-year-old South Asian female with a medical history of atrial fibrillation with a prior cerebrovascular event (stroke) approximately 2 months prior, chronic kidney disease stage 3b and moderate dementia initially presented (March 2019) with severe dyspnea and worsening pedal edema during the preceding week. Her vital signs indicated systolic blood pressures of 160 mmHg, heart rate of 143 beats per minute, respiratory rate of 24 breaths per minute with an oxygen saturation of 92% on room air. Her physical examination revealed atrial fibrillation, an elevated jugular venous pressure of 12 cm H2O, an S3 gallop with occasional bibasilar crackles and moderate pitting edema. A 12-lead electrocardiogram confirmed atrial fibrillation with a rapid ventricular response and non-specific ST-T changes. Portable chest radiography revealed florid pulmonary edema with diffuse Kerley B lines and prominent hilar congestion. Pertinent diagnostic laboratory investigations included a d-dimer 323 ng/dL (normal ≤500 ng/mL), pro-brain natriuretic peptide 3468 pg/mL (normal ≤300 pg/mL), cardiac biomarkers, CK-MB 7 U/L (normal <20 U/L), troponin I 0.03 ng/
Routine investigations revealed a hemoglobin of 9.2 g/dL (normal 12–15 g/dL) with a normal white cell count and serum creatinine of 1.6 mg/dL (normal 0.6–1.2 mg/dL). She was initiated on renally dosed enoxaparin, low-dose beta-blockade, and diuresis with a furosemide bolus, and infusion in the emergency department and subsequently admitted for further hospitalization.

Bedside transthoracic echocardiography demonstrated a large 59 mm × 43 mm mass arising from the left atrial free wall (see Figure 1(a)–(c)). There was preserved left ventricular systolic function (ejection fraction of 65%) without regional wall motion abnormalities. In addition, there was moderate left atrial enlargement (38 mL/m²) with severe diastolic dysfunction and restrictive physiology with an estimated left atrial pressure of 22 mmHg and moderate pulmonary hypertension of 52 mmHg. There was no overt prolapse of the myxoma through the mitral valve orifice during the time of the study.

Due to the patient’s advanced age, high clinical frailty scale, and moderate dementia, a non-invasive, conservative medical strategy was adopted after achieving a consensus among family members. Diagnostic coronary angiography, advanced imaging with computed tomography and magnetic resonance modalities, and open-heart surgical excision were deferred. She was instituted on daily low-dose apixaban, bisoprolol, rosuvastatin, amlodipine with hydralazine and nitrates, and furosemide to attenuate polypharmacy while maintaining euvolemia.6–10 Sacubitril/valsartan and spironolactone were avoided due to her chronic kidney disease and concern of precipitating electrolyte derangements such as hyperkalemia. Ivabradine was not utilized as the patient had chronic atrial fibrillation. The patient’s ensuing 4-day hospitalization course was uneventful, and her blood pressures and heart rate gradually normalized. She was safely discharged on an individualized medical regimen with routine follow-up appointments and full-time home-health nursing (see Figure 2). The patient was asymptomatic and hemodynamically stable at her 3-month appointment (June 2019); however, unfortunately, expired during sleep (October 2019) before her 6-month appointment (after her index hospitalization), and the family deferred a post-mortem.

Figure 1. Two-dimensional transthoracic (TTE) series: (a) 2D-TTE parasternal long-axis view displaying the atrial myxoma during diastole (enveloped by the red circumferential border), (b) 2D-TTE parasternal long-axis magnified/zoomed-in view illustrating the extent of tumor burden and the myxoma’s attachment to the left atrial-free wall, and (c) 2D-TTE parasternal long-axis view illustrating the tumor dimensions of 59 mm × 43 mm in the top left corner.

Figure 2. Censored photograph of the patient a few days after hospital discharge. The white arrow indicates that her pedal edema has since mostly resolved.
Discussion

This case is unique, as to the best of the authors’ knowledge; it is the eldest patient described to have a suspected atrial myxoma. Unfortunately, it could not be verified by histopathology or imaging modalities such as computed tomography or cardiac magnetic resonance imaging (cMRI) due to the conservative approach. The tentative diagnosis was entirely reliant on transthoracic echocardiography, which, albeit possesses a 95% sensitivity. This is considered the first-line diagnostic test in clinching a prompt and accurate diagnosis, whereas its more invasive counterpart, transesophageal echocardiography, provides 100% sensitivity. Cardiac MRI is rapidly gaining traction as a novel imaging modality in the assessment of cardiac myxomas; however, was not performed in this case due to patient’s claustrophobia. It provides superior tissue characterization by differentiating myxomas from thrombus, and benign from malignant lesions, without exposure to ionizing radiation.

The patient’s overall presentation was consistent with that of heart failure with preserved ejection fraction (HFpEF) exacerbation. The etiology was considered multifactorial and likely contributed by a pseudo-stenotic effect of the myxoma, hypertensive urgency, and atrial fibrillation with a rapid ventricular response, which may or may not have been related to the myxoma. Dyspnea and palpitations were the most common symptoms on index presentation, being 70% and 35%, respectively. Our patient had atrial fibrillation, which was coincident in almost 30% of patients. The emergence of heart failure is contingent on tumor location and burden in creating a pseudo-stenotic effect due to malapposition of mitral valve leaflets and obstructive physiology within the left ventricular outflow tract. Also, it has been postulated that a paraneoplastic cytokine milieu may induce myocardial inflammation and resultant ischemia. Coronary embolization of tumor fragments may also be implicated in the pathogenesis of incident heart failure; however, angiography was deferred in preference to a non-invasive approach. Our patient did also report a plethora of non-specific constitutional symptoms, which can often mimic rheumatologic disease and be overlooked, especially in the geriatric population, obfuscating the eventual diagnosis.

Due to the advent of novel imaging technologies and, generally, longer life expectancy, the incidence of myxomas in the geriatric population has increased. Atrial myxomas presenting in the seventh decade is rare, with only a paucity of published case reports. At the turn of the last century, Bire et al. discovered only 19 confirmed cases of septuagenarians and elder with myxomas. An updated review reported just more than 60 individuals with myxoma, with their ages ranging from 68 to 88, and the eldest patient undergoing successful resection being a Japanese man, aged 90. In an older series of 100 individuals with atrial myxoma, almost one-fifth were aged 70 and older. With respect to geriatric patients, a recent study evaluated elective surgery in elderly patients with myxomas. During the time frame, 1985–2012, 17 consecutive patients (mean age ~69 ± 4 years) were evaluated. Overall, 13 patients survived resection with a relatively high mortality rate of nearly 25%. The patient’s calculated EuroSCORE II was approximately 8%. In light of this information, and the fact that our patient was almost 20 years older than the mean study population, a non-invasive management plan was adopted.

The patient also had a medical history of the prior cerebrovascular event 2 months earlier, which could have possibly resulted from systemic embolization (10%-45%) from the atrial myxoma or a cardioembolic attributed to atrial fibrillation, which in turn could be sequelae of the myxoma itself. As there was no mitral valve disease, the patient was initiated on low-dose daily apixaban for direct oral anticoagulation, given her chronic kidney disease 3b and HAS-BLED score of 4, clinically translating to a near 9% risk of a major bleeding event. As the patient possessed several features for excessive polypharmacy such as frailty, multimorbidity, and dementia, meticulous care was taken in individualizing evidence-based therapies with minimal drug–drug interactions.

Conclusion

We describe a rare case of a giant atrial myxoma in a nonagenarian, which was medically managed. Myxomas are among the great mimickers, with a myriad of clinical presentations and should be considered as a differential diagnosis for heart failure in a geriatric population.

Key clinical message

The clinician should be aware of atrial myxoma as an etiology for heart failure in geriatric patients.

Authors’ contributorship

J.K., R.S., V.S., S.P., S.M., and N.A.S. all contributed equally in writing the manuscript. All authors read and approved the final manuscript.

Compliance with ethics guidelines and standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Copyright permission

The patient’s power of attorney (the patient has moderate to severe dementia) has provided written, informed consent to have the details of her case published. Institutional approval was not required for publication.

Data sharing statement

All available data can be obtained by contacting the corresponding author.
Declaration of conflicting interests

The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Ethics approval

Our institution does not require ethical approval for reporting individual cases or case series.

Funding

The author(s) received no financial support for the research, authorship, and/or publication of this article.

Informed consent

Written informed consent was obtained from a legally authorized representative(s) for anonymized patient information to be published in this article.

ORCID iD

Naveen Anand Seecheran https://orcid.org/0000-0002-7779-0181

References

1. Ladich E and Virmani R. Tumors of the cardiovascular system. In: LM Buja and R Butany (eds) Cardiovascular Pathology. London: Academic Press, 2016, pp. 735–772.
2. Zipes DP, Libby P, Bonow RO, et al. Braunwald’s heart disease e-book: a textbook of cardiovascular medicine. Philadelphia, PA: Elsevier, 2018, p. 2040.
3. Biswas A and Thakur AK. An unusual presentation of atrial myxoma in an elderly patient: a case report. Cases J 2008; 1: 384.
4. Matsumura Y, Nakashima Y, Noguchi T, et al. Giant left atrial myxoma in a nonagenarian. J Am Geriatr Soc 2013; 61(1): 169–170.
5. Pinede L, Duhaut P and Loire R. Clinical presentation of left atrial cardiac myxoma. Medicine 2001; 80(3): 159–172.
6. Siontis KC, Zhang X, Eckard A, et al. Faculty of 1000 evaluation for outcomes associated with apixaban use in end-stage kidney disease patients with atrial fibrillation in the United States. Circulation 2018; 138: 1519–1529.
7. Van Gelder IC, Hobbelt AH, Mulder BA, et al. Rate control in atrial fibrillation: many questions still unanswered. Circulation 2015; 132(17): 1597–1599.
8. Oesterle A, Laufs U and Liao JK. Pleiotropic effects of statins on the cardiovascular system. Circ Res 2017; 120(1): 229–243.
9. Pfeffer MA and Skali H. PRAISE (prospective randomized amlodipine survival evaluation) and criticism. JACC Heart Fail 2013; 1(4): 315–317.
10. Cohn JN. A-HeFT: old dog, new endothelial tricks. Tex Heart Inst J 2005; 32(3): 366–368.
11. Reynen K. Cardiac myxomas. N Engl J Med 1995; 333: 1610–1617.
12. Abbas A, Garfath-Cox KAG, Brown IW, et al. Cardiac MR assessment of cardiac myxomas. Br J Radiol 2015; 88(1045): 20140599.
13. Mousavi N, Cheezum MK, Aghayev A, et al. Assessment of cardiac masses by cardiac magnetic resonance imaging: histological correlation and clinical outcomes. J Am Heart Assoc 2019; 8(1): e007829.
14. Kolleru A, Desai D and Cohen GI. The etiology of atrial myxoma tumor plop. J Am Coll Cardiol 2011; 57(21): e371.
15. Boyacioglu K, Dommez AA, Aksut M, et al. Surgical management of cardiac myxomas in elderly patients. BMB 2016; 1: 1–5.
16. Chiariello GA, Bruno P, Colizzi C, et al. Acute heart failure related to a large left atrial myxoma. Proc(Bayl Univ Med Cent) 2018; 31: 331–333.
17. Kanda T and Takahashi T. Interleukin-6 and cardiovascular diseases. Jpn Heart J 2004; 45: 183–193.
18. Umeyama S. Clinical and immunohistochemical findings in cardiac myxoma with special reference to the expression of interleukin-6. KITAKANTO Med J 1994; 44(5): 475–484.
19. Mahmoud DAF, Faqi Mahmoud DA, Aldoori JS, et al. Giant left atrial myxoma in an elderly man: case report. Case Rep Clin Med 2014; 3: 226–230.
20. Rajab TK, Shekar P and Falk RH. Myxoma, dyspnoea, tinnitus, scoliosis, and alopecia. Lancet 2011; 377(9774): 1378.
21. Vasquez A, Sethi G, Maximon M, et al. Atrial myxomas in the elderly: a case report and review of the literature. Am J Geriatr Cardiol 2004; 13(1): 39–44.
22. Bire F, Roudaut R, Chevalier JM, et al. Cardiac myxoma in patients over 75 years of age. Report of 19 cases. Arch Mal Coeur Vaiss 1999; 92(3): 323–328.
23. Vicari RM, Polanco E, Schechtmann N, et al. Atrial myxoma presenting with orthostatic hypotension in an 84-year-old Hispanic man: a case report. J Med Case Rep 2009; 3: 9328.
24. Loire R. Myxoma of the left atrium, clinical outcome of 100 operated patients. Arch Mal Coeur Vaiss 1996; 89(9): 1119–1125.
25. Roques F. The logistic EuroSCORE. Eur Heart J 2003; 24: 881–882.
26. Pisters R, Lane DA, Nieuwlaat R, et al. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 2010; 138(5): 1093–1100.
27. Schafer JH, Casey AL, Dupre KA, et al. Safety and efficacy of apixaban versus warfarin in patients with advanced chronic kidney disease. Am Pharmacother 2018; 52(11): 1078–1084.
28. Patterson SM, Cadogan CA, Kerse N, et al. Interventions to improve the appropriate use of polypharmacy for older people. Cochrane Database Syst Rev 2014; 10: CD008165.
29. Gnjidic D, Le Couteur DG, Kouladjian L, et al. Deprescribing trials: methods to reduce polypharmacy and the impact on prescribing and clinical outcomes. Clin Geriatr Med 2012; 28(2): 237–253.